Giuseppe Barbaro

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11774532/publications.pdf

Version: 2024-02-01

97	4,118	87843 38	114418 63
papers	citations	h-index	g-index

98	98	98	3760
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Incidence of Dilated Cardiomyopathy and Detection of HIV in Myocardial Cells of HIV-Positive Patients. New England Journal of Medicine, 1998, 339, 1093-1099.	13.9	283
2	Threshold Values of Highâ€risk Echocardiographic Epicardial Fat Thickness. Obesity, 2008, 16, 887-892.	1.5	223
3	Highly Active Antiretroviral Therapy: Current State of the Art, New Agents and Their Pharmacological Interactions Useful for Improving Therapeutic Outcome. Current Pharmaceutical Design, 2005, 11, 1805-1843.	0.9	222
4	Cardiovascular Manifestations of HIV Infection. Circulation, 2002, 106, 1420-1425.	1.6	176
5	Cardiac Involvement in the Acquired Immunodeficiency Syndrome: A Multicenter Clinical-Pathological Study. AIDS Research and Human Retroviruses, 1998, 14, 1071-1077.	0.5	170
6	Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. Journal of Hepatology, 2001, 35, 406-411.	1.8	117
7	Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: An italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology, 1998, 28, 374-378.	3.6	112
8	Primary Pulmonary Hypertension in HIV Patients: A Systematic Review. Angiology, 2001, 52, 31-41.	0.8	109
9	Pathogenesis of HIV-associated cardiovascular complications. Lancet Infectious Diseases, The, 2001, 1, 115-124.	4.6	106
10	Cardiac Metabolism in Myocardial Ischemia. Current Pharmaceutical Design, 2008, 14, 2551-2562.	0.9	97
11	Intensity of Myocardial Expression of Inducible Nitric Oxide Synthase Influences the Clinical Course of Human Immunodeficiency Virus-Associated Cardiomyopathy. Circulation, 1999, 100, 933-939.	1.6	93
12	Relation of Subepicardial Adipose Tissue to Carotid Intima-Media Thickness in Patients With Human Immunodeficiency Virus. American Journal of Cardiology, 2007, 99, 1470-1472.	0.7	93
13	Relationship of epicardial fat thickness and fasting glucose. International Journal of Cardiology, 2008, 128, 424-426.	0.8	93
14	Prevalence of Dilated Cardiomyopathy in HIV-Infected African Patients Not Receiving HAART: A Multicenter, Observational, Prospective, Cohort Study in Rwanda. Current HIV Research, 2007, 5, 129-137.	0.2	82
15	An open-label, prospective, observational study of the incidence of coronary artery disease in patients with hiv infection receiving highly active antiretroviral therapy. Clinical Therapeutics, 2003, 25, 2405-2418.	1.1	79
16	Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. American Journal of Medicine, 1999, 107, 112-118.	0.6	74
17	Metabolic and Cardiovascular Complications of Highly Active Antiretroviral Therapy for HIV Infection. Current HIV Research, 2006, 4, 79-85.	0.2	74
18	Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects. Obesity, 2014, 22, 332-336.	1.5	69

#	Article	IF	Citations
19	HIV-Associated Coronary Arteritis in a Patient with Fatal Myocardial Infarction. New England Journal of Medicine, 2001, 344, 1799-1800.	13.9	68
20	Highly Active Antiretroviral Therapyâ€“Associated Metabolic Syndrome: Pathogenesis and Cardiovascular Risk*. American Journal of Therapeutics, 2006, 13, 248-260.	0.5	68
21	Cardiovascular Manifestations of HIV Infection. Journal of the Royal Society of Medicine, 2001, 94, 384-390.	1.1	64
22	Incidence of the involvement of the cardiovascular system in HIV infection. Aids, 2003, 17, S46-S50.	1.0	63
23	HIV infection and cancer in the era of highly active antiretroviral therapy (Review). Oncology Reports, 2007, 17, 1121-6.	1.2	60
24	Relationships between Body Fat Distribution, Epicardial Fat and Obstructive Sleep Apnea in Obese Patients with and without Metabolic Syndrome. PLoS ONE, 2012, 7, e47059.	1.1	58
25	Phosphodiesterase 5 Inhibitors - Drug Design and Differentiation Based on Selectivity, Pharmacokinetic and Efficacy Profiles. Current Pharmaceutical Design, 2006, 12, 3459-3465.	0.9	57
26	HAART Drugs Induce Mitochondrial Damage and Intercellular Gaps and gp120 Causes Apoptosis. Cardiovascular Toxicology, 2004, 4, 327-338.	1.1	52
27	Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Current Diabetes Reports, 2009, 9, 37-42.	1.7	52
28	Association of epicardial fat thickness with the severity of obstructive sleep apnea in obese patients. International Journal of Cardiology, 2013, 167, 2244-2249.	0.8	52
29	Epicardial adipose tissue feeding and overfeeding the heart. Nutrition, 2019, 59, 1-6.	1.1	52
30	Epicardial Adipose Tissue is Related to Carotid Intima-Media Thickness and Visceral Adiposity in HIV-Infected Patients with Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome. Current HIV Research, 2007, 5, 275-279.	0.2	51
31	Relation of Epicardial Fat and Alanine Aminotransferase in Subjects With Increased Visceral Fat. Obesity, 2008, 16, 179-183.	1.5	51
32	Visceral Fat as Target of Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome. Current Pharmaceutical Design, 2007, 13, 2208-2213.	0.9	50
33	Interferon-Î±-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-Î± alone: an italian multicenter, randomized, controlled, clinical study. American Journal of Gastroenterology, 1998, 93, 2445-2451.	0.2	49
34	Interferon-Î±-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-Î± alone: an italian multicenter, randomized, controlled, clinical study. American Journal of Gastroenterology, 1998, 93, 2445-2451.	0.2	48
35	Chronic pharmacological treatment in takotsubo cardiomyopathy. International Journal of Cardiology, 2008, 127, 121-123.	0.8	48
36	Early Impairment of Systolic and Diastolic Function in Asymptomatic HIV-Positive Patients: A Multicenter Echocardiographic and Echoâ€“Doppler Study. AIDS Research and Human Retroviruses, 1996, 12, 1559-1563.	0.5	44

#	Article	IF	Citations
37	The Pavia consensus statement. Aids, 2003, 17, S170-S179.	1.0	44
38	Pathogenesis of HIVâ€Associated Cardiomyopathy. Annals of the New York Academy of Sciences, 2001, 946, 57-81.	1.8	40
39	HIV-Associated Cardiomyopathy. Herz, 2005, 30, 486-492.	0.4	39
40	HIV infection, highly active antiretroviral therapy and the cardiovascular system. Cardiovascular Research, 2003, 60, 87-95.	1.8	36
41	Kawasaki-like syndromes and other vasculitic syndromes in HIV-infected patients. Aids, 2003, 17, S77-S82.	1.0	36
42	Pathogenesis of HIV-associated heart disease. Aids, 2003, 17, S12-S20.	1.0	34
43	Impairment of diastolic function in adult patients affected by osteogenesis imperfecta clinically asymptomatic for cardiac disease: Casuality or causality?. International Journal of Cardiology, 2009, 131, 200-203.	0.8	33
44	HIV-associated cardiovascular complications: A new challenge for emergency physicians. American Journal of Emergency Medicine, 2001, 19, 566-574.	0.7	32
45	Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome and Cardiovascular Risk. Chemotherapy, 2006, 52, 161-165.	0.8	32
46	Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Journal of Hepatology, 2000, 33, 448-455.	1.8	31
47	HIV infection and the cardiovascular system. AIDS Reviews, 2002, 4, 93-103.	0.5	31
48	Clinical findings of Takotsubo cardiomyopathy: results from a multicenter international study. Journal of Cardiovascular Medicine, 2008, 9, 239-244.	0.6	29
49	Clinical course of cardiomyopathy in HIV-infected patients with or without encephalopathy related to the myocardial expression of tumour necrosis factor-Î± and nitric oxide synthase. Aids, 2000, 14, 827-838.	1.0	27
50	Chronic sildenafil in men with diabetes and erectile dysfunction. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 451-464.	1.5	27
51	Inverse Association of Circulating SIRT1 and Adiposity: A Study on Underweight, Normal Weight, and Obese Patients. Frontiers in Endocrinology, 2018, 9, 449.	1.5	27
52	Highly Active Antiretroviral Therapy and Cardiovascular Complications in HIV-Infected Patients. Current Pharmaceutical Design, 2003, 9, 1475-1481.	0.9	25
53	Heart and HAART: Two sides of the coin for HIV-associated cardiology issues. World Journal of Cardiology, 2010, 2, 53.	0.5	24
54	Cardiovascular disease burden among human immunodeficiency virus-infected individuals. International Journal of Cardiology, 2018, 265, 195-203.	0.8	23

#	Article	IF	Citations
55	Human immunodeficiency virus & cardiovascular risk. Indian Journal of Medical Research, 2011, 134, 898.	0.4	21
56	Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study. European Journal of Gastroenterology and Hepatology, 2002, 14, 477-483.	0.8	19
57	Severe growth hormone deficiency and empty sella in obesity: a cross-sectional study. Endocrine, 2015, 49, 503-511.	1.1	19
58	Incidence of the involvement of the cardiovascular system in HIV infection. Aids, 2003, 17 Suppl 1, S46-50.	1.0	19
59	Pharmacological Therapy in Children with Atrial Fibrillation and Atrial Flutter. Current Pharmaceutical Design, 2008, 14, 770-775.	0.9	16
60	Blood SIRT1 Shows a Coherent Association with Leptin and Adiponectin in Relation to the Degree and Distribution of Adiposity: A Study in Obesity, Normal Weight and Anorexia Nervosa. Nutrients, 2020, 12, 3506.	1.7	15
61	HIV-Associated Myocarditis. Heart Failure Clinics, 2005, 1, 439-448.	1.0	13
62	Takotsubo-Like Left Ventricular Dysfunction in an HIV-Infected Patient. Current HIV Research, 2006, 4, 239-241.	0.2	13
63	Protrhombotic Effects of Contraceptives. Current Pharmaceutical Design, 2010, 16, 3490-3496.	0.9	13
64	New Options in the Treatment of Lipid Disorders in HIV-Infected Patients. Open AIDS Journal, 2009, 3, 31-37.	0.1	12
65	Cardiovascular complications in the acquired immunodeficiency syndrome. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2009, 55, 621-630.	0.3	11
66	Patent Foramen Ovale and Thromboembolic Complications. Current Pharmaceutical Design, 2010, 16, 3497-3502.	0.9	11
67	Epicardial adipose tissue and signs of metabolic syndrome in children. Eating and Weight Disorders, 2016, 21, 269-276.	1.2	10
68	Methadone and QT prolongation in HIV-infected patients. American Journal of Cardiology, 2004, 94, 147-148.	0.7	9
69	Vasculitic Syndromes in HIV-Infected Patients. , 2003, 40, 185-196.		8
70	Good Safety Profile and Efficacy of Leucocyte Interferon-?? in Combination with Oral Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C. BioDrugs, 2003, 17, 433-439.	2.2	7
71	Highly Active Antiretroviral Therapy and the Cardiovascular System: The Heart of the Matter. Pharmacology, 2003, 69, 177-179.	0.9	7
72	The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome. Current Pharmaceutical Design, 2008, 14, 2605-2612.	0.9	7

#	Article	IF	Citations
73	Treatment of Tako-tsubo cardiomyopathy. International Journal of Cardiology, 2008, 130, 475-476.	0.8	6
74	Selenium deficiency and HIV-associated cardiomyopathy. Journal of the Royal Society of Medicine, 2002, 95, 57-57.	1.1	5
75	Increased Access to the Emergency Department for Coronary Heart Disease of HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy. Annals of Emergency Medicine, 2002, 40, 530-531.	0.3	4
76	Pathogenesis of HIV-Associated Cardiovascular Disease. , 2003, 40, 49-70.		4
77	Evolution of the Involvement of the Cardiovascular System in HIV Infection. , 2003, 40, 15-22.		4
78	Editorial [Hot Topic:Metabolic Therapy: An Important Therapeutic Option for the Treatment of Cardiovascular Diseases (Executive Editors: G.M.C. Rosano and G. Barbaro)]. Current Pharmaceutical Design, 2008, 14, 2519-2520.	0.9	4
79	HIV Infection, Antiretroviral Therapy and Cardiovascular Risk. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 295-300.	3.1	3
80	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 295-300.	1.5	3
81	Long-term effects of protease-inhibitor-based combination therapy. Lancet, The, 2004, 363, 900.	6.3	3
82	Cardiovascular monitoring of HIV-infected patients. Journal of Cardiovascular Medicine, 2006, 7, 379.	0.6	3
83	Targeting the organ-specific adiposity. Eating and Weight Disorders, 2019, 24, 1-2.	1.2	3
84	HIV-associated cardiomyopathy is not Keshan disease. Journal of the Royal Society of Medicine, 2002, 95, 324-324.	1.1	3
85	Protease Inhibitors and Mortality among Children and Adolescents Infected with HIV-1. New England Journal of Medicine, 2002, 346, 1026-1027.	13.9	2
86	Guidelines for the Prevention and Management of Cardiovascular Complications in HIV-Infected Patients Receiving HAART: The Pavia Consensus Statement. , 2003, 40, 226-232.		2
87	Clinical and biological insights in HIV-associated cardiovascular disease in the era of highly active antiretroviral therapy. Aids, 2003, 17, S1-S3.	1.0	2
88	HIV-Associated Lipodystrophy: Pathogenesis and Clinical Features. , 2003, 40, 97-104.		2
89	Selenium Deficiency and HIV-Associated Cardiomyopathy. Journal of the Royal Society of Medicine, 2002, 95, 57-57.	1.1	1
90	Threshold Values of High-risk Echocardiographic Epicardial Fat Thickness. Obesity, 0, , .	1.5	1

#	Article	IF	Citations
91	Heterosexual transmission of HIV-1 infection in UK. Lancet, The, 2001, 358, 1458.	6.3	0
92	Appendix. , 2003, 40, 233-240.		0
93	Regarding: Right ventricular cardiac dysfunction in HIV-infected patients studied with radionuclide ventriculography. American Heart Journal, 2004, 148, e2.	1.2	0
94	Editorial [Hot Topic: New Potential Pharmaceutical Targets of Metabolic Syndrome (Executive Editors:) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.9	0
95	Editorial [Current Trends in the Treatment of Supraventricular Tachycardia in Pediatric Age Executive Editors: S. Novo and G. Barbaro]. Current Pharmaceutical Design, 2008, 14, 722-722.	0.9	0
96	Editorial [Hot topic: Antithrombotic Therapy in Cardiovascular and Haematological Diseases: New Perspectives (Executive Editors: Sergio Siragusa, Giuseppe Barbaro and Giovanni Fazio)]. Current Pharmaceutical Design, 2010, 16, 3435-3435.	0.9	0
97	Sequelae of Chronic Viral Hepatitis. , 0, , 371-388.		0